Forte Biosciences (FBRX) Reports Q2 Loss of $9.52

Forte Biosciences (NASDAQ: FBRX) reported Q2 EPS of ($9.52), versus ($0.30) reported last year.

“We are very happy to have concluded the reverse merger on June 15th and in that process, brought on a very well-respected group of investors, including Alger, BVF Partners, Franklin Templeton and OrbiMed to support Forte as we continue to grow the company. Our lead program, FB-401, developed in collaboration with the National Institute of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has shown great potential in the initial Phase 1/2a study in mild, moderate and severe atopic dermatitis patients, including adults and children as young as 3 years old.” said Paul Wagner, Ph.D., CEO of Forte Biosciences “We look forward to further validating FB-401’s potential with the randomized trial in mild to moderate atopic dermatitis patients, including adults and children 2 years of age and older, which will be initiating shortly. There is a particular need for safe and effective atopic dermatitis therapies for children.”

For earnings history and earnings-related data on Forte Biosciences (FBRX) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Drive Group and Innoviz target $20M in LiDAR security sales by 2027
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity